Baxter reinstated with a Buy at Goldman Sachs

Goldman Sachs reinstated coverage of Baxter (BAX) with a Buy rating and $42 price target Over the next several quarters, the firm expects the company to make “meaningful progress” toward margin and cash flow improvement, driving its earnings above consensus estimates. Baxter’s risk/reward is skewed positively at current levels, the analyst tells investors in a research note.